All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).
Saved in:
| Title: | All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE). |
|---|---|
| Authors: | Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Cuglievan B; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX., El Hajjar G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Jen WY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Bataller A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Duose DY; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Housto, TX., Zhang B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Housto, TX., Furudate K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Ning J; Department of Statistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Xiao L; Department of Statistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Mouhayar E; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX., Pinto A; Pupil Bio, Houston, TX., Bidikian A; Department of Internal Medicine, Yale School of Medicine and Yale New Haven Hospital, New Haven, CT., Thompson E; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Farhat A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., McCall D; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Tan S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Bazinet A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. |
| Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Jun 11, pp. JCO2601159. Date of Electronic Publication: 2026 Jun 11. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
